| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.04B | 39.97B | 39.73B | 39.57B | 36.74B | 35.64B |
| Gross Profit | 12.08B | 11.99B | 12.07B | 11.61B | 10.73B | 10.04B |
| EBITDA | 3.19B | 3.36B | 3.66B | 3.40B | 2.56B | 2.22B |
| Net Income | 1.45B | 1.47B | 1.70B | 1.48B | 1.14B | 915.00M |
Balance Sheet | ||||||
| Total Assets | 53.18B | 53.24B | 54.08B | 50.76B | 49.38B | 47.52B |
| Cash, Cash Equivalents and Short-Term Investments | 14.15B | 14.18B | 11.20B | 12.12B | 12.34B | 11.53B |
| Total Debt | 1.09B | 1.08B | 1.19B | 668.00M | 691.00M | 697.00M |
| Total Liabilities | 15.92B | 15.72B | 16.91B | 16.51B | 16.13B | 15.23B |
| Stockholders Equity | 36.65B | 36.60B | 36.33B | 33.52B | 32.60B | 31.69B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.64B | 24.00M | 891.00M | 1.30B | 1.80B |
| Operating Cash Flow | 0.00 | 4.43B | 795.00M | 1.78B | 2.06B | 2.59B |
| Investing Cash Flow | 0.00 | -381.00M | -817.00M | -908.00M | -753.00M | -777.00M |
| Financing Cash Flow | 0.00 | -1.15B | -978.00M | -1.19B | -631.00M | -626.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥17.81B | 10.48 | ― | 3.58% | -3.74% | 3.99% | |
80 Outperform | ¥19.49B | 11.28 | ― | 3.09% | 0.27% | 7.57% | |
74 Outperform | ¥17.96B | 11.80 | ― | 2.81% | 0.23% | -8.64% | |
74 Outperform | ¥29.41B | 10.69 | ― | 7.56% | 8.01% | 13.19% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
55 Neutral | ¥21.55B | -8.36 | ― | 4.35% | -4.00% | -386.52% | |
52 Neutral | ¥22.74B | -5.06 | ― | 4.03% | 1.03% | -92.80% |
Fukuvi Chemical Industry reported consolidated net sales of ¥30.2 billion for the nine months ended Dec. 31, 2025, up 0.5% year on year, with operating profit slipping 1.7% to ¥1.25 billion but ordinary profit edging 1.3% higher and profit attributable to owners of the parent jumping 19.5%. Earnings per share rose to ¥63.62, equity-to-asset ratio improved to 71.2%, and the company kept its dividend policy on track, maintaining a full-year forecast of ¥41.46 billion in sales and a 36.8% rise in operating profit, underlining expectations of profit growth and continued shareholder returns despite modest top-line expansion.
The board plans total annual dividends of ¥27 per share for the fiscal year ending March 31, 2026, up from ¥26 a year earlier, signaling confidence in cash flow and profitability. With no changes in accounting policies or consolidation scope and a stable share count aside from a modest reduction in treasury shares, the guidance implies stronger margins and reinforces Fukuvi’s positioning as a financially robust player, which could support valuation and reassure stakeholders amid a relatively flat revenue environment.
The most recent analyst rating on (JP:7871) stock is a Hold with a Yen1013.00 price target. To see the full list of analyst forecasts on Fukuvi Chemical Industry Co., Ltd. stock, see the JP:7871 Stock Forecast page.